On the morning of June 13, Professor Wen-Chun Qu, Director of Regenerative Pain Medicine at Mayo Clinic, Director of Mayo Center for Cell and Gene Therapy, and Director of GMP Biomanufacturing Center, led a delegation to visit Deep Harbour Cell Valley. The delegation was warmly received by Professor Yuan-Yuan Shi, founder of Deep Harbour Cell Valley, Professor David Jin, Chief Medical Expert, and Professor Jian-Xun Wang, Chief Scientist, who engaged in academic exchanges and jointly explored strategic cooperation directions.

This visit coincides with a critical juncture in the development of China's cell therapy industry. With the release of policy incentives,Deep Harbour Cell Valley, as the first foreign-invested demonstration project for cell and gene therapy technology applications in the Shenzhen Shekou Free Trade Zone, is accelerating the internationalization of domestic cell products. Professor Qu Wenchun conducted a focused inspection of the international business headquarters of Cell Valley Group—Deep Harbour Cell Valley. Professor Qu expressed high praise for Cell Valley's R&D, production processes, and quality control systems for cell therapy drugs such as CAR-T, CAR-NK, and exosomes. Both parties reached preliminary strategic cooperation intentions regarding CAR-T target screening, large-scale production of viral vectors, and clinical translation research. Professor Shi Yuanyuan stated: "Leveraging the policy advantages of the Qianhai Free Trade Zone, we look forward to collaborating with Mayo Clinic to establish an international benchmark for clinical translation of cell therapies, promoting the global benefit of innovative achievements."

This collaboration will enhance Cell Valley's international influence in the field of cell therapy.